GSK's Respiratory Drug Nucala Meets Goal in COPD Study - Regeneron Pharmaceuticals ( NASDAQ:REGN ) , GSK ( NYSE:GSK )
GSK's GSK phase III study evaluating its blockbuster drug Nucala ( mepolizumab ) , an anti-IL5 biologic, for treating chronic obstructive pulmonary disease ( COPD ) , met its primary endpoint.
| Ticker |
Sentiment |
Impact |
|
AZN
|
Neutral
|
9 %
|
|
GSK
|
Neutral
|
34 %
|
|
SNY
|
Somewhat Bullish
|
17 %
|
